Terms: = Breast cancer AND PALB2, ENSG00000083093, 79728
686 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of breast cancer-Associated Germline Pathogenic Variants in Mexico.
Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
[TBL] [Abstract] [Full Text] [Related]
3. Association Between Polymorphisms in DNA Damage Repair Pathway Genes and Female breast cancer Risk.
Wang Y; Sun Y; Tan M; Lin X; Tai P; Huang X; Jin Q; Yuan D; Xu T; He B
DNA Cell Biol; 2024 May; 43(5):219-231. PubMed ID: 38634815
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
[TBL] [Abstract] [Full Text] [Related]
5. palb2-mutated human mammary cells display a broad spectrum of morphological and functional abnormalities induced by increased TGFβ signaling.
Tuppurainen H; Laurila N; Nätynki M; Eshraghi L; Tervasmäki A; Erichsen L; Sørensen CS; Pylkäs K; Winqvist R; Peltoketo H
Cell Mol Life Sci; 2024 Apr; 81(1):173. PubMed ID: 38597967
[TBL] [Abstract] [Full Text] [Related]
6. Genetic analysis of palb2 gene WD40 domain in canine mammary tumour patients.
Çıldır ÖŞ; Özmen Ö; Kul S; Rişvanlı A; Özalp G; Sabuncu A; Kul O
Vet Med Sci; 2024 May; 10(3):e1366. PubMed ID: 38527110
[TBL] [Abstract] [Full Text] [Related]
7. Two Germline Pathogenic Variants in cancer Susceptibility Genes and Their Null Implication in breast cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing.
Rezqallah A; Torres-Esquius S; Llop-Guevara A; Cruellas M; Martinez MT; Romey M; Denkert C; Serra V; Chirivella I; Balmaña J
JCO Precis Oncol; 2024 Mar; 8():e2300446. PubMed ID: 38513169
[TBL] [Abstract] [Full Text] [Related]
8. PARP Inhibitors for breast cancer Treatment: A Review.
Morganti S; Marra A; De Angelis C; Toss A; Licata L; Giugliano F; Taurelli Salimbeni B; Berton Giachetti PPM; Esposito A; Giordano A; Bianchini G; Garber JE; Curigliano G; Lynce F; Criscitiello C
JAMA Oncol; 2024 May; 10(5):658-670. PubMed ID: 38512229
[TBL] [Abstract] [Full Text] [Related]
9. Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study.
Augustinsson A; Loman N; Ehrencrona H
Breast Cancer Res Treat; 2024 Jun; 205(3):599-607. PubMed ID: 38491334
[TBL] [Abstract] [Full Text] [Related]
10. Pleomorphic/solid lobular carcinoma of male breast with palb2 germline mutation: case report and literature review.
Rogges E; Corati T; Amato M; Campagna D; Farro J; De Toffol S; Fortunato L; Costarelli L
Pathologica; 2024 Feb; 116(1):62-68. PubMed ID: 38482676
[TBL] [Abstract] [Full Text] [Related]
11. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive Inherited Risk Estimation for Risk-Based breast cancer Screening in Women.
Mars N; Kerminen S; Tamlander M; Pirinen M; Jakkula E; Aaltonen K; Meretoja T; Heinävaara S; Widén E; Ripatti S;
J Clin Oncol; 2024 May; 42(13):1477-1487. PubMed ID: 38422475
[TBL] [Abstract] [Full Text] [Related]
13. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
14. Cost-Effectiveness of Population-Based Multigene Testing for breast and Ovarian cancer Prevention.
Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
[TBL] [Abstract] [Full Text] [Related]
15. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and breast cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract] [Full Text] [Related]
16. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract] [Full Text] [Related]
17. Investigation of Genetic Alterations Associated With Interval breast cancer.
Rodriguez J; Grassmann F; Xiao Q; Eriksson M; Mao X; Bajalica-Lagercrantz S; Hall P; Czene K
JAMA Oncol; 2024 Mar; 10(3):372-379. PubMed ID: 38270937
[TBL] [Abstract] [Full Text] [Related]
18. The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative breast cancers.
Aguilar-Mahecha A; Alirezaie N; Lafleur J; Bareke E; Przybytkowski E; Lan C; Cavallone L; Salem M; Pelmus M; Aleynikova O; Greenwood C; Lovato A; Ferrario C; Boileau JF; Mihalcioiu C; Roy JA; Marcus E; Discepola F; Majewski J; Basik M
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254917
[TBL] [Abstract] [Full Text] [Related]
19. Counselling Framework for Germline
Wong SM; Apostolova C; Eisenberg E; Foulkes WD
Curr Oncol; 2024 Jan; 31(1):350-365. PubMed ID: 38248108
[TBL] [Abstract] [Full Text] [Related]
20. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones E; Raghunandan M; Robbez-Masson L; Magraner-Pardo L; Alaguthurai T; Yablonovitch A; Yen J; Xiao H; Brough R; Frankum J; Song F; Yeung J; Savy T; Gulati A; Alexander J; Kemp H; Starling C; Konde A; Marlow R; Cheang M; Proszek P; Hubank M; Cai M; Trendell J; Lu R; Liccardo R; Ravindran N; Llop-Guevara A; Rodriguez O; Balmana J; Lukashchuk N; Dorschner M; Drusbosky L; Roxanis I; Serra V; Haider S; Pettitt SJ; Lord CJ; Tutt ANJ
Ann Oncol; 2024 Apr; 35(4):364-380. PubMed ID: 38244928
[TBL] [Abstract] [Full Text] [Related]
[Next]
